Literature DB >> 3770052

Standardization of steroid receptor assays in human breast cancer--IV. Long-term within- and between-laboratory variation of estrogen and progesterone receptor assays.

A Koenders, S M Thorpe.   

Abstract

One batch of lyophilized calf uterine cytosol was analyzed for estrogen and progesterone receptor (ER and PgR, respectively) content by 12 members of the EORTC Receptor Group on three different occasions over a total study period of 1 yr: One vial was included with each of 20 consecutive batches of routine tumor analyses between December 1983 and May 1984. Two vials were simultaneously assayed between July and August 1984 (within-run variation). One vial was analyzed at the end of 1984 (November-December). The overall mean ER and PgR values did not change systematically over the total study period of 1 yr. Within the various laboratories, the between-run variations of both ER and PgR assays were considerable and differed from one institution to another (7-26%). For both ER and PgR measurements the average within-run (n = 2) and between-run (n = 20) coefficients of variation were similar (8-9% and 16-17%, respectively). Comparison of the results from multiple sequential assays (c.v. = 12.9%) with those from single assays (c.v. = 21.2%) showed that about 60% of the between-laboratory variance in ER could be explained on the basis of the between-run variance. With regard to PgR analysis, however, the between-laboratory variance decreased only 25%. Standardized use of one type of protein assay (Coomassie brilliant blue) and a standard protein solution (human serum albumin) has decreased the between-laboratory variation of the protein analysis results to less than 15%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770052     DOI: 10.1016/0277-5379(86)90061-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  8 in total

1.  Quality control in immunocytochemistry: experiences with the oestrogen receptor assay.

Authors:  F T Bosman; A F de Goeij; M Rousch
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

2.  Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses.

Authors:  H C van Doorn; C W Burger; P van der Valk; H M Bonfrèr
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

3.  Improvement of quality control for steroid receptor measurements: analysis of distributions in more than 40000 primary breast cancers. French Study Group on Tissue and Molecular Biopathology.

Authors:  S Romain; F Spyratos; J Goussard; J L Formento; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays.

Authors:  S M Thorpe
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

5.  Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis.

Authors:  H M Scheres; A F De Goeij; M J Rousch; G G Hondius; D D Willebrand; A H Gijzen; F T Bosman
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

6.  Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E.O.R.T.C. Receptor Group.

Authors:  M A Blankenstein
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

7.  TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1.

Authors:  Florence Gizard; Romain Robillard; Olivier Barbier; Brigitte Quatannens; Anne Faucompré; Françoise Révillion; Jean-Philippe Peyrat; Bart Staels; Dean W Hum
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

8.  Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors.

Authors:  J A Søreide; O A Lea; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.